ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,236.47
-0.78%
Dow Jones
38,263.74
-1.09%
US Dollar vs MXN
17.70915
4.23%
Brent Oil
78.28
-3.12%
Bitcoin
68,886.17
1.68%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Recursion Pharmaceuticals Inc (RXRX)

  7. Recursion Pharmaceuticals Inc (RXRX) Noticias

RXRX Recursion Pharmaceuticals Inc

8.45
0.17 (2.05%)
Última actualización: 11:57:48
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Recursion Pharmaceuticals Inc RXRX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.17 2.05% 8.45 11:57:48
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
8.39 8.34 8.86 8.28
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
03/6/202408:00GLOBERecursion to Participate in Upcoming Investor Conferences
30/5/202417:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/5/202415:03EDGAR2Form 144 - Report of proposed sale of securities
29/5/202414:27GLOBEPower of Recursion OS on Display at Genome Scale in Nature..
24/5/202415:35EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
24/5/202415:31EDGAR2Form 8-K - Current report
24/5/202415:30GLOBERecursion Appoints Robert Hershberg M.D., Ph.D, as New Chair..
17/5/202418:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202418:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202418:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202418:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202415:25EDGAR2Form 144 - Report of proposed sale of securities
13/5/202404:00GLOBERecursion Announces Completion of NVIDIA-Powered BioHive-2,..
09/5/202415:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202415:01GLOBERecursion Provides Business Updates and Reports First..
02/5/202407:00GLOBERecursion to Report First Quarter 2024 Business Updates and..
01/5/202407:01GLOBERecursion to Participate in Upcoming Investor Conferences
30/4/202407:00GLOBEAltitude Lab Secures Small Business Administration Growth..
16/4/202407:00GLOBERecursion Appoints Najat Khan, PhD, as Chief R&D Officer and..
02/4/202407:00GLOBERecursion to Participate in Upcoming Investor Conference
26/3/202407:00GLOBERecursion Publishes Annual Environmental, Social and..
11/3/202403:00GLOBERecursion Announces Plans to Open New Office in London
08/3/202418:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202417:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202416:39EDGAR2Form 144 - Report of proposed sale of securities
06/3/202415:59EDGAR2Form 144 - Report of proposed sale of securities
05/3/202415:18EDGAR2Form 144 - Report of proposed sale of securities
01/3/202413:58GLOBERecursion Hosts Second Annual Rare Disease Day Events for..
01/3/202406:59GLOBERecursion to Participate in Upcoming Investor Conferences
29/2/202407:25EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202415:05GLOBERecursion Provides Business Updates and Reports Fourth..
23/2/202418:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202417:13EDGAR2Form 144 - Report of proposed sale of securities
21/2/202416:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202415:29EDGAR2Form 144 - Report of proposed sale of securities
20/2/202406:59GLOBERecursion to Host Public L(earnings) Call on February 27
16/2/202418:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202418:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202418:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202415:50EDGAR2Form 144 - Report of proposed sale of securities
13/2/202418:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202418:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202418:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202417:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202415:18EDGAR2Form 144 - Report of proposed sale of securities
12/2/202411:21EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202416:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202417:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
RXRX
Recursion Pharmaceuticals
USOTC
CDUAF
Canadian Utilities (PK)
LSE
44SE
Inter-amer
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados